Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the U.S. Food and Drug Administration ( FDA ...
Approximately 200,000 patients in the United States have PPF, with limited treatment options Topline data expected in the second half of 2027
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
United Therapeutics: Q2 Earnings Snapshot
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter...
Barchart Research What to Expect from UTHR Earnings UTHR Generated August 4, 2026 Current Price $518.68 EPS Estimate $$6.82 Consensus Rating Moderate Buy Average Move 6.67% United Therapeutics Reports...
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow